Delivery Order SPE2DB24D1205-SPE2DB25FCZZZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 21, 2025, for TEZSPIRE 210 mg/1.91 mL pen auto-injectors. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of August 11, 2025. The contract will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $4,687.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen auto-injectors on August 28, 2025, with a completion date of September 19, 2025. This non-set-aside competitive award is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injections on August 5, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of TEZSPIRE 210 mg/1.91 ml auto-injector pens valued at $4,687.18. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The contract requires completion by September 3, 2025, with performance taking place at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL pen injectors. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a standard...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors on July 31, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 21, 2025, with performance taking place at the vendor's corporate headquarters in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for Tezspire 210 mg/1.91 mL pen auto-injectors valued at $4,687.18, with completion scheduled for August 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was awarded through open competition. The contract is to be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $7,030.77 and is scheduled for completion by September 12, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price delivery order, valued at $4,687.18, carries an ultimate completion date of August 21, 2025, and represents a non-competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZZZDelivery Order
The Defense Logistics Agency awarded a $28,123.08 delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 ml pen auto-injectors on September 2, 2025, with completion targeted for September 23, 2025. This firm fixed-price contract represents a direct delivery order with no set-aside designation, utilizing open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and distribution operations supporting federal medical procurement. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), a comprehensive $999,999,999 global pharmaceutical support vehicle extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical supply chains, AmerisourceBergen supplies the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with a wide range of pharmaceuticals and medical supplies. TEZSPIRE is a specialty biologic medication used for severe eosinophilic asthma treatment, reflecting the company's portfolio of advanced therapeutic options supporting military and veteran healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.1k | 9/2/25 |